08:33 AM EDT, 09/16/2024 (MT Newswires) -- AstraZeneca ( AZN ) said Monday that its Himalaya phase 3 trial assessing Imfinzi combined with Imjudo showed a "sustained, clinically meaningful overall survival benefit" at five years for patients with unresectable hepatocellular carcinoma.

The trial was limited to patients who had not previously received systemic treatment and were not eligible for localized therapy, the company said.

A single dose of the combined treatment at five years of follow-up decreased the risk of death by 24% versus the drug sorafenib, AstraZeneca ( AZN ) said, adding that nearly 19.6% of patients receiving the combination therapy were alive at five years compared with 9.4% for those receiving the sorafenib treatment.

The company also said that 17.5% of patients receiving the combination therapy experienced serious treatment-related adverse events, including death, compared with 9.9% of patients receiving the sorafenib treatment.

Price: 79.45, Change: +1.18, Percent Change: +1.51